Q3 2024 Lantern Pharma Inc Earnings Call Transcript
Key Points
- Lantern Pharma Inc (LTRN) has made significant clinical progress with its AI-guided drug programs, including the ongoing Phase 2 HARMONIC trial and Phase 1 programs for LP-184 and LP-284.
- The company received FDA Fast Track designation for LP-184 in glioblastoma, highlighting the potential to expedite development and enhance commercial value.
- Lantern Pharma Inc (LTRN) is expanding its HARMONIC trial into Asia, specifically Japan and Taiwan, to address a larger portion of never smoker lung cancer cases.
- The company has secured three new FDA rare pediatric designations for LP-184, which could lead to valuable priority review vouchers upon FDA approval.
- Lantern Pharma Inc (LTRN) closed the quarter with approximately $28.1 million in cash, providing a cash runway into at least late 2025.
- Lantern Pharma Inc (LTRN) reported a net loss of approximately $4.5 million for the third quarter of 2024, an increase from the previous year's third quarter loss.
- R&D expenses increased significantly to approximately $3.7 million, driven by heightened clinical trial activity.
- The company faces risks and uncertainties related to forward-looking statements, including clinical trial results and competition impact.
- General and administrative expenses rose to approximately $1.5 million, primarily due to increased professional and legal fees.
- Lantern Pharma Inc (LTRN) is still in early discussions for potential partnerships, particularly for its never smoker trial in Asia, indicating a lack of immediate partnership agreements.
Good afternoon, and welcome to our third-quarter 2024 earnings call. As a reminder, this call is being recorded (Operator Instructions) A webcast replay of today's conference call will be available on our website at lanternpharma.com.
Shortly after the call, we issued a press release after market close today summarizing our financial results and progress across the company for the third quarter ended September 30, 2024. A copy of this release is available through our website at lanternpharma.com where you will also find a link to the slides management will be referencing on today's call.
We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
